Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

about

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.Outcomes of patients with renal monoclonal immunoglobulin deposition disease.

P2860

Q38807562-78761F45-ED1A-4222-9C0F-135F70908327 Q40533557-2A4FCEC9-6BE1-4043-95B5-755A5AC06E7A

P2860

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

Item

http://www.wikidata.org/entity/Q53562807

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@en

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@nl

type

Item

label

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@en

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@nl

prefLabel

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@en

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@nl

P1476

Outcomes of light-chain amyloi ...... ective multicenter assessment.

@en

P2093

Celia Suriu

http://www.w3.org/2001/XMLSchema#string

Eli Muchtar

http://www.w3.org/2001/XMLSchema#string

Evgeni Chubar

http://www.w3.org/2001/XMLSchema#string

Hila Magen

http://www.w3.org/2001/XMLSchema#string

Irit Avivi

http://www.w3.org/2001/XMLSchema#string

Israeli MM study group

http://www.w3.org/2001/XMLSchema#string

Izhar Hardan

http://www.w3.org/2001/XMLSchema#string

Julia Jakubinsky

http://www.w3.org/2001/XMLSchema#string

Moshe E Gatt

http://www.w3.org/2001/XMLSchema#string

Mouna Ballan-Haj

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma

Amyloidosis: pathogenesis and new therapeutic options.

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Dangerous small B-cell clones.

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Light chain amyloidosis 2012: a new era.

Light chain amyloidosis: the heart of the problem.

P304

136-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12558

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25827161

http://www.w3.org/2001/XMLSchema#string

P921

collaboration

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

about

P2860

P2860

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921